Evommune EVMN
NYSE EVMN
$7.82 -0.80 (-9.28%)
As of: Nov 12, 2026 · 10:18 AM EST

Evommune (EVMN) Income After Tax (2024 - 2026)

Updated

Evommune (EVMN) posted Income After Tax of -$32.24 million for Q2 2026, compared with -$22.59 million a year earlier.

Analysis

Evommune (EVMN) Income After Tax (2024 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Income After Tax at Evommune was -$94.65 million; for FY2025, it was -$77.75 million.

  • In prior years, Evommune's Income After Tax was -$66.77 million in FY2024.
  • The Q2 2026 figure stands as the lowest quarterly Income After Tax in data going back to Q3 2024.
  • According to Business Quant data, Income After Tax for the three prior quarters was -$21.67 million (Q1 2026), -$28.27 million (Q4 2025) and -$12.47 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income After Tax (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 210.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 4.22 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.07 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.80 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 3.86 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 2.43 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 3.25 Bn
10 Evommune 285.17 Mn -352.34 Mn - -32.24 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.24 Mn
Mar 31, 2026 -21.67 Mn
Dec 31, 2025 -28.27 Mn
Sep 30, 2025 -12.47 Mn
Jun 30, 2025 -22.59 Mn
Mar 31, 2025 -14.42 Mn
Dec 31, 2024 -20.73 Mn
Sep 30, 2024 -15.90 Mn
API Access

Evommune Income After Tax API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=profit-after-tax&ticker=EVMN&period=max&api_key=YOUR_API_KEY